港股异动 | 李氏大药厂(00950)涨超7% ZK2401于中国提交新药临床试验申请已获NMPA受理

智通财经08-14

智通财经APP获悉，李氏大药厂(00950)涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验(IND)申请已获得中国国家药品监督管理局(NMPA)药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物(ADC)项目，由李氏大药厂拥有该分子的完整全球知识产权。ZK2401建基于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2659119634?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-14 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659119634","market":"us","top_or_hot":-1,"title":"港股异动 | 李氏大药厂(00950)涨超7% ZK2401于中国提交新药临床试验申请已获NMPA受理","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，李氏大药厂(00950)涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验(IND)申请已获得中国国家药品监督管理局(NMPA)药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物(ADC)项目，由李氏大药厂拥有该分子的完整全球知识产权。ZK2401建基于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1479979.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 李氏大药厂(00950)涨超7% ZK2401于中国提交新药临床试验申请已获NMPA受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 李氏大药厂(00950)涨超7% ZK2401于中国提交新药临床试验申请已获NMPA受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-14 15:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1479979.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，李氏大药厂(00950)涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验(IND)申请已获得中国国家药品监督管理局(NMPA)药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物(ADC)项目，由李氏大药厂拥有该分子的完整全球知识产权。ZK2401建基于李氏...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1479979.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMED","symbol_name":"iShares Health Innovation Active ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1479979.html","article_id":"2659119634","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659119634","pubTimestamp":1786692986,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，李氏大药厂涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验申请已获得中国国家药品监督管理局药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物项目，由李氏大药厂拥有该分子的完整全球知识产权。作为李氏大药厂ADC平台的首个项目，ZK2401标志着本集团推进该平台发展的一个重要起点。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BMED":"iShares Health Innovation Active ETF","PSYK":"PSYK ETF","BK1587":"次新股","MDTX":"Corgi MediaTek 2x Daily ETF","VXUS":"国际股票ETF-Vanguard","BK1574":"生物医药B类股","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","00950":"李氏大药厂","BK1583":"高瓴概念","KCAI":"KraneShares China Alpha Index ETF","06622":"兆科眼科-B","BK1191":"制药","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Hong Kong stock changes | Lee's Pharmaceuticals (00950) rose by more than 7% ZK2401 submitted a new drug clinical trial application in China and has been accepted by NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":1.5,"BMED":1.5,"VXUS":1.5,"PSYK":1.5,"06622":1.5,"IBBQ":1.5,"MDTX":1.5,"KCAI":1.5,"IBBJ":1.5},"content_text":"智通财经APP获悉，李氏大药厂(00950)涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验(IND)申请已获得中国国家药品监督管理局(NMPA)药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物(ADC)项目，由李氏大药厂拥有该分子的完整全球知识产权。ZK2401建基于李氏大药厂自主研发的抗PD-L1抗体索卡佐利单抗(Socazolimab)，并偶联新型拓扑异构酶I抑制剂载荷。作为李氏大药厂ADC平台的首个项目，ZK2401标志着本集团推进该平台发展的一个重要起点。董事会认为，提交此项IND申请为本集团肿瘤领域创新管线的一个重要里程碑。该项目体现李氏大药厂在完全自主开发创新生物及ADC资产方面的持续独立研发能力，并符合本集团策略重点，即专注于以专利技术为基础、具有重大临床潜力及有防守竞争优势的差异化产品。截至目前，索卡佐利单抗已获中国NMPA批准上市，用于两项适应症：联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)，以及治疗复发性或转移性宫颈癌。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2659119634","isCrawlerRequest":true}